MENLO PARK, Calif.--(

加州门洛公园--(

BUSINESS WIRE

商业热线

)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35

)--生物制药公司AN2 Therapeutics，Inc.（纳斯达克股票代码：ANTX）今天宣布，联合创始人、董事长、总裁兼首席执行官埃里克·伊萨姆将出席奥本海默35

th

第

Annual Healthcare Life Sciences Conference.

年度保健生命科学会议。

Details of the event are as follows:

活动详情如下：

Oppenheimer 35

奥本海默35

th

第

Annual Healthcare Life Sciences Conference (virtual)

年度医疗保健生命科学会议（虚拟）

Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.

联合创始人、董事长、总裁兼首席执行官埃里克·伊瑟姆（EricEasom）将于2025年2月12日（星期三）美国东部时间下午3:20提供公司概况。

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at

演示文稿的网络广播可在AN2 Therapeutics网站的投资者部分访问

www.an2therapeutics.com

www.an2therapeutics.com

. An archived replay will be available for at least 30 days following the presentation.

。演示后至少30天内将提供存档的重播。

About AN2 Therapeutics, Inc.

关于AN2 Therapeutics，Inc。

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

。AN2拥有一条用于恰加斯病、NTM和类鼻疽的硼基化合物开发管道，以及专注于传染病和肿瘤学目标的早期项目。

For more information, please visit our website at .

有关更多信息，请访问我们的网站：。

www.an2therapeutics.com

www.an2therapeutics.com

.

.